Browse our 650+ Publications​

Latest Publications

The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders

Pagliuca S, et al.
Blood
February 2022
Authors and Affiliates
Simona Pagliuca 1,2, Carmelo Gurnari 1,3, Hassan Awada 1, Ashwin Kishtagari 1, Sunisa Kongkiatkamon 1, Laila Terkawi 1, Misam Zawit 1, Yihong Guan 1, Thomas LaFramboise 4, Babal K Jha 1, Bhumika J Patel 5, Betty K Hamilton 6, Navneet S Majhail 6, Sofie Lundgren 7,8, Satu Mustjoki 7,8,9, Yogen Saunthararajah 1, Valeria Visconte 1, Timothy A Chan 10, Chao-Yie Yang 11, Tobias L Lenz 12,13, Jaroslaw P Maciejewski 1; 1 Translational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, OH. 2 University of Paris, Paris, France. 3 Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. 4 Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH. 5 Leukemia Program, Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH. 6 Blood and Marrow Transplant Program, Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH. 7 Hematology Research Unit Helsinki, University of Helsinki-Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. 8 Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland. 9 ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland. 10 Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH. 11 Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN. 12 Research Group for Evolutionary Immunogenomics, Max Planck Institute for Evolutionary Biology, Plön, Germany; and. 13 Research Unit for Evolutionary Immunogenomics, Department of Biology, University of Hamburg, Hamburg, Germany.

HLA-dependent variation in SARS-CoV-2 CD8+ T cell cross-reactivity with human coronaviruses

Buckely PR, et al.
immunology
February 2022
Authors and Affiliates
Paul R Buckley 1,2, Chloe H Lee 1,2, Mariana Pereira Pinho 1, Rosana Ottakandathil Babu 1,2, Jeongmin Woo 1,2, Agne Antanaviciute 1,2, Alison Simmons 1, Graham Ogg 1, Hashem Koohy 1,2; 1 MRC Human Immunology Unit, Medical Research Council (MRC) Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine (WIMM), John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom. 2 MRC WIMM Centre for Computational Biology, Medical Research Council (MRC) Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.

Early versus late response to daratumumab-based triplet therapies in patients with multiple myeloma: a pooled analysis of trials POLLUX, CASTOR and MAIA.

Wang J, et al.
Leukemia & Lymphoma
February 2022
Authors and Affiliates
Jiasheng Wanga , Raul Arroyo-Suarezb, Srilatha Dasarib, Kanithra Sekaranb and William Tsec aDepartment of Hematology and Oncology, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; bDepartment of Internal Medicine, MetroHealth Medical Center, Cleveland, OH, USA; cDepartment of Hematology and Oncology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.

Cavo M, et al.
Blood
February 2022
Authors and Affiliates
Michele Cavo,1 Jesus San-Miguel,2 Saad Z. Usmani,3 Katja Weisel,4 Meletios A. Dimopoulos,5 Herve Avet-Loiseau,  6 Bruno Paiva,2 Nizar J. Bahlis,7 Torben Plesner,8 Vania Hungria,9 Philippe Moreau,10 Maria-Victoria Mateos,11 Aurore Perrot,12 Shinsuke Iida,13 Thierry Facon,14 Shaji Kumar,15 Niels W. C. J. van de Donk,16 Pieter Sonneveld,17 Andrew Spencer,18 Maria Krevvata,19 Christoph Heuck,19 Jianping Wang,20 Jon Ukropec,21 Rachel Kobos,19 Steven Sun,20 Mia Qi,20 and Nikhil Munshi22,23 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seragnoli ”, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Universita di Bologna, Bologna, Italy;  2 Clınica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBER-ONC, Pamplona, Spain; 3Levine Cancer Institute/Atrium Health, Charlotte, NC; 4Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 5National and Kapodistrian University of Athens, Athens, Greece; 6Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France; 7Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada; 8Vejle Hospital and University of Southern Denmark, Vejle, Denmark; 9 Clinica Medica Sao Germano, S ao Paulo, Brazil; 10Hematology, University Hospital Hotel-Dieu, CHU Nantes, Nantes, France; 11University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain; 12Hematology Department, University Cancer Institute IUCT, Toulouse, France; 13Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Mizuho-ku Nagoya, Japan; 14University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France; 15Department of Hematology, Mayo Clinic Rochester, Rochester, MN; 16Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; 17Erasmus MC, Rotterdam, The Netherlands; 18Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia; 19Janssen Research & Development, LLC, Spring House, PA; 20Janssen Research & Development, LLC, Raritan, NJ; 21Janssen Global Medical Affairs, Horsham, PA; 22Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; and 23Veterans Administration Boston Healthcare System, West Roxbury, MA

Decade-long leukaemia remissions with persistence of CD4 + CAR T cells

Melenhorst JJ, et al.
February 2022
Authors and Affiliates
J Joseph Melenhorst #,1,2,3,4,5, Gregory M Chen #,6, Meng Wang #,7,8,9, David L Porter #,9,10, Changya Chen 11,12, McKensie A Collins 7,8,9,13, Peng Gao 11,12, Shovik Bandyopadhyay 13, Hongxing Sun 7,8,9, Ziran Zhao 7,8,9, Stefan Lundh 7,8,9, Iulian Pruteanu-Malinici 14, Christopher L Nobles 15, Sayantan Maji 7,8,9, Noelle V Frey 9, Saar I Gill 9, Lifeng Tian 7,9, Irina Kulikovskaya 7,8,9, Minnal Gupta 7,8,9, David E Ambrose 7,8,9, Megan M Davis 7,8,9, Joseph A Fraietta 7,8,9,15, Jennifer L Brogdon 14, Regina M Young 7,8,9, Anne Chew 7,8,9, Bruce L Levine 7,8,9, Donald L Siegel 7,8,16, Cécile Alanio 17,18,19, E John Wherry 17,18,19, Frederic D Bushman 15, Simon F Lacey 7,8,9, Kai Tan 20,21,22,23,24, Carl H June 25,26,27,28,29; 1 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu. 2 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu. 3 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu. 4 Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@pennmedicine.upenn.edu. 5 Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, USA. mej@pennmedicine.upenn.edu. 6 Graduate Group in Genomics and Computational Biology, University of Pennsylvania, Philadelphia, PA, USA. 7 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 8 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 9 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 10 Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 11 Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, PA, USA. 12 Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. 13 Graduate Group in Cell & Molecular Biology, University of Pennsylvania, Philadelphia, PA, USA. 14 Novartis Institute for Biomedical Research, Cambridge, MA, USA. 15 Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 16 Department of Transfusion Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 17 Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 18 Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, USA. 19 Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 20 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. tank1@chop.edu. 21 Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. tank1@chop.edu. 22 Graduate Group in Genomics and Computational Biology, University of Pennsylvania, Philadelphia, PA, USA. tank1@chop.edu. 23 Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA. tank1@chop.edu. 24 Graduate Group in Cell & Molecular Biology, University of Pennsylvania, Philadelphia, PA, USA. tank1@chop.edu. 25 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 26 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 27 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 28 Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 29 Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, USA. cjune@upenn.edu. # Contributed equally.

Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer

Chun B, et al.
Journal for ImmunoTherapy of Cancer
February 2022
Authors and Affiliates
Brie Chun 1, Joanna Pucilowska 2, ShuChing Chang 3, Isaac Kim 1, Benjamin Nikitin 1, Yoshinobu Koguchi 1, William L Redmond 1, Brady Bernard 1 4, Venkatesh Rajamanickam 1,4, Nathan Polaske 5, Paul A Fields 5, Valerie Conrad 1, Mark Schmidt 1, Walter J Urba 1, Alison K Conlin 1, Heather L McArthur 6, David B Page 7; 1 Earle A Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA. 2 Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA. 3 Medical Data Research Center, Providence St Joseph Health, Portland, Oregon, USA. 4 Computational Immuno-Oncology and Bioinformatics Core, Earle A. Chiles Research Institute, Portland, Oregon, USA. 5 Adaptive Biotechnologies Corp, Seattle, Washington, USA. 6 Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 7 Earle A Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA david.page2@providence.org.

Multi-objective optimization reveals time- and dose-dependent inflammatory cytokine-mediated regulation of human stem cell derived T-cell development

Edgar JM, et al.
npj Regenerative Medicine
February 2022
Authors and Affiliates
John M Edgar 1, Yale S Michaels 1, Peter W Zandstra 2,3; 1 School of Biomedical Engineering, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada. 2 School of Biomedical Engineering, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada. peter.zandstra@ubc.ca. 3 Michael Smith Laboratories, University of British Columbia, Vancouver, BC, V6T 1Z4, Canada. peter.zandstra@ubc.ca.

Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy

Bonaventura P, et al.
Science Advances
February 2022
Authors and Affiliates
Paola Bonaventura 1,2, Vincent Alcazer 1, Virginie Mutez 3, Laurie Tonon 4, Juliette Martin 5, Nicolas Chuvin 3, Emilie Michel 3, Rasha E Boulos 3, Yann Estornes 3, Jenny Valladeau-Guilemond 1, Alain Viari 4, Qing Wang 6, Christophe Caux 1,2, Stéphane Depil 1,2,3,7; 1 Centre de Recherche en Cancérologie de Lyon (CRCL), UMR INSERM U1052 CNRS 5286, Lyon, France. 2 Centre Léon Bérard, Lyon, France. 3 ErVaccine Technologies, Lyon, France. 4 Synergie Lyon Cancer, Plateforme de bioinformatique « Gilles Thomas », Lyon, France. 5 CNRS-Institut de Biologie et Chimie des Protéines UMR 5086, Lyon, France. 6 Complete Omics, Baltimore, MD, USA. 7 Université Claude Bernard Lyon 1, Lyon, France.

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.

San-Miguel J, et al.
Blood
January 2022
Authors and Affiliates
Jesus San-Miguel,1 Herve Avet-Loiseau, 2 Bruno Paiva,1 Shaji Kumar,3 Meletios A. Dimopoulos,4 Thierry Facon,5 Marıa-Victoria Mateos, 6Cyrille Touzeau,7 Andrzej Jakubowiak,8 Saad Z. Usmani,9 Gordon Cook,10 Michele Cavo,11 Hang Quach,12 Jon Ukropec,13 Priya Ramaswami,14 Huiling Pei,14 Mia Qi,15 Steven Sun,15 Jianping Wang,15 Maria Krevvata,16 Nikki DeAngelis,16 Christoph Heuck,16 Rian Van Rampelbergh,17 Anupa Kudva,15 Rachel Kobos,15 Ming Qi,16 and Nizar J. Bahlis,18 1Clınica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain; 2Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France; 3Department of Hematology, Mayo Clinic, Rochester,MN; 4National and Kapodistrian University of Athens, Athens, Greece; 5University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France; 6University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain; 7Hematology, University Hospital Hotel-Dieu, Nantes, France; 8University of Chicago Medical Center, Chicago, IL; 9Levine Cancer Institute/Atrium Health, Charlotte, NC; 10Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom; 11IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seragnoli, ” Universita di Bologna, Bologna, Italy; 12University of Melbourne, St. Vincent’s Hospital, Melbourne, VIC; 13Janssen Global Medical Affairs, Horsham, PA; 14Janssen Research & Development, LLC, Titusville, NJ; 15Janssen Research & Development, LLC, Raritan, NJ; 16Janssen Research & Development, LLC, Spring House, PA; 17Janssen Research & Development, Beerse, Belgium; and 18Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada